M&A / Deals AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid Pharmaceutical TechnologyAbbVie's deal with Haisco comes as many pharma companies look to restock their pipelines amid looming global patent expiries.M&A / DealsPain & AnaesthesiaRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaceutical Technology AbbVie’s deal with Haisco comes as many pharma companies look to restock their pipelines amid looming global patent expiries. M&A / DealsPain & AnaesthesiaRead full story Post navigation Previous: FDA issues complete response letter to Replimune’s RP1 for melanomaNext: AbbVie enters world of pain in up to $715M deal with China’s Haisco Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
